Sight Sciences, Inc. (SGHT) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
SGHT Revenue Growth
Revenue Breakdown (FY 2025)
SGHT's revenue distribution by segment and geography for fiscal year 2025
By Product/Segment
SGHT Revenue Analysis (2018–2025)
As of May 8, 2026, Sight Sciences, Inc. (SGHT) generated trailing twelve-month (TTM) revenue of $79.6 million, reflecting strong growth of +12.5% year-over-year. The most recent quarter (Q1 2026) recorded $19.7 million in revenue, down 3.4% sequentially.
Looking at the longer-term picture, SGHT's 5-year compound annual growth rate (CAGR) stands at +22.9%, indicating outstanding long-term growth trajectory. The company achieved its highest annual revenue of $81.1 million in 2023.
Revenue diversification analysis shows SGHT's business is primarily driven by Surgical Glaucoma (98%), and Dry Eye (2%). With over half of revenue concentrated in Surgical Glaucoma, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including GKOS (+36.3% YoY), ATRC (+15.0% YoY), and NVCR (+8.5% YoY), SGHT has underperformed the peer group in terms of revenue growth. Compare SGHT vs GKOS →
SGHT Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| SGHTCurrent | $80M | +12.5% | +22.9% | -48.0% | |
 GKOS | $507M | +36.3% | +17.7% | -17.1% | |
 ATRC | $535M | +15.0% | +20.9% | -0.6% | |
 NVCR | $655M | +8.5% | +5.8% | -23.5% | |
 HOLX | $4.1B | +2.2% | +1.7% | 17.4% | |
 MASI | $1.5B | -14.4% | +5.9% | 20.5% |
SGHT Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $77.4M | -3.1% | $66.7M | 86.2% | $-37,099,000 | -48.0% |
| 2024 | $79.9M | -1.5% | $68.3M | 85.5% | $-50,532,000 | -63.3% |
| 2023 | $81.1M | +13.6% | $69.2M | 85.3% | $-57,274,000 | -70.7% |
| 2022 | $71.3M | +45.7% | $59.0M | 82.7% | $-83,954,000 | -117.7% |
| 2021 | $49.0M | +77.1% | $40.3M | 82.4% | $-51,478,000 | -105.2% |
| 2020 | $27.6M | +18.4% | $18.4M | 66.7% | $-32,188,000 | -116.5% |
| 2019 | $23.3M | +210.1% | $16.8M | 72.0% | $-24,039,000 | -103.0% |
| 2018 | $7.5M | - | $5.2M | 69.0% | $-14,297,000 | -189.9% |
See SGHT's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SGHT Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SGHT vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSGHT — Frequently Asked Questions
Quick answers to the most common questions about buying SGHT stock.
Is SGHT's revenue growth accelerating or slowing?
SGHT maintains +12.5% revenue growth, in line with its 5-year CAGR of +22.9%. TTM revenue stands at $80M. Growth rate remains consistent with historical average.
What is SGHT's long-term revenue growth rate?
Sight Sciences, Inc.'s 5-year revenue CAGR of +22.9% reflects the sustained expansion pattern. Current YoY growth of +12.5% is near this long-term average.
How is SGHT's revenue distributed by segment?
SGHT reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.